Trials / Completed
CompletedNCT00234858
Tarka vs. Hyzaar in Patients With Metabolic Syndrome (STAR)
A Phase IV, Randomized, Open-Label, Active Controlled Study to Compare the Effects of Tarka® and Hyzaar® on Glucose Tolerance in Subjects With Metabolic Syndrome
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 280 (actual)
- Sponsor
- Abbott · Industry
- Sex
- All
- Age
- 21 Years
- Healthy volunteers
- Not accepted
Summary
The primary objective of this study is to determine whether impaired glucose tolerance is improved to a greater degree by Tarka than Hyzaar in subjects with metabolic syndrome
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | trandolapril/verapamil | 2/180 mg QD with titration if needed at Week 4 to 4/240 mg QD |
| DRUG | (Hyzaar) losartan/hydrochlorothiazide | 50/12.5 mg QD with titration if needed at Week 4 to 100/25 mg QD |
Timeline
- Start date
- 2004-03-01
- Primary completion
- 2006-04-01
- First posted
- 2005-10-10
- Last updated
- 2008-07-15
Source: ClinicalTrials.gov record NCT00234858. Inclusion in this directory is not an endorsement.